New molecular and biochemical insights of doxorubicin-induced hepatotoxicity

Pureti Lakshmi Prasanna1, Kaviyarasi Renu1, Abilash Valsala Gopalakrishnan1

  • 1Department of Biomedical Sciences, School of Biosciences and Technology, VIT, Vellore, Tamil Nadu 632014, India.

Life Sciences
|April 3, 2020
PubMed

Insights

Doxorubicin chemotherapy causes liver damage by increasing oxidative stress and inflammation. This review explores molecular mechanisms of doxorubicin-induced hepatotoxicity and potential protective agents.

Area of Science:

  • Pharmacology
  • Toxicology
  • Hepatology

Background:

  • Doxorubicin, an anthracycline chemotherapy, causes significant toxicity in non-cancerous tissues.
  • The liver, crucial for detoxification, is a primary target for doxorubicin-induced damage (hepatotoxicity).

Purpose of the Study:

  • To investigate the molecular mechanisms underlying doxorubicin-induced hepatotoxicity.
  • To review factors contributing to liver damage and potential therapeutic interventions.

Main Methods:

  • Literature review focusing on molecular mechanisms of doxorubicin hepatotoxicity.
  • Analysis of liver serum biomarkers, oxidative stress markers, antioxidant enzyme activity, and mitochondrial function.

Main Results:

  • Doxorubicin treatment leads to hepatocyte vacuolation, degeneration, bile duct hyperplasia, and necrosis.
  • Elevated liver enzymes (ALT, AST, SGOT, SGPT, LDH), bilirubin, and creatine kinase indicate hepatic damage.
  • Increased reactive oxygen species (ROS), oxidative stress (Nrf-2, FOXO-1, HO-1 surge), and inflammation, alongside decreased antioxidant activity (SOD, GPx, CAT), characterize the toxicity.
  • Mitochondrial dysfunction and enhanced apoptosis contribute to liver injury.

Conclusions:

  • Doxorubicin-induced hepatotoxicity is primarily mediated by ROS production, oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis.
  • Medicinal plant extracts, natural products, and chemical agents show potential in alleviating doxorubicin-induced liver damage.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
125
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
165
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.2K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
152
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
471
Peroxisomes01:24

Peroxisomes

Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
19.8K